Ertugliflozin tied to improved glycemic control in T2DM

February 20, 2018

(HealthDay)—For adults with inadequately controlled type 2 diabetes, ertugliflozin treatment is associated with improved glycemic control over 52 weeks, according to a study published online Feb. 8 in Diabetes, Obesity and Metabolism.

Ronnie Aronson, M.D., from LMC Diabetes & Endocrinology in Ontario, and colleagues conducted a phase III randomized trial to examine the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 despite diet and exercise. The study comprised a 26-week placebo-controlled period where 461 participants received placebo or ertugliflozin (5 or 15 mg/day) and a second 26-week period in which in the had blinded metformin added.

The researchers found that the mean change in glycated hemoglobin (HbA1c) from baseline to week 52 was −0.9 and −1 percent in the ertugliflozin 5- and 15-mg groups, respectively; the proportion of patients with HbA1c <7 percent was 25.6 and 28.5 percent, respectively, at week 52. Ertugliflozin was correlated with a reduction in fasting plasma glucose, body weight, and systolic blood pressure. In females, the incidence of genital mycotic infections (GMIs) was significantly higher in both the 5- and 15-mg ertugliflozin groups versus placebo/metformin (26.9 and 29 versus 9.9 percent); males had significantly higher GMI incidence in the 15-mg group (7.8 versus 1.2 percent).

"Ertugliflozin treatment over 52 weeks improved and reduced body weight and systolic blood pressure but increased GMIs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer and Merck & Co., which funded the study.

Explore further: Addition of DPP4i to AGI reduces HbA1c in T2DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Addition of DPP4i to AGI reduces HbA1c in T2DM

October 5, 2017
(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), inadequately controlled with alpha-glucosidase inhibitors (AGIs), the addition of a dipeptidyl peptidase-4 (DPP4) inhibitor (DPP4i) is associated with a greater ...

Ranolazine added to glimepiride cuts HbA1c in T2DM

January 18, 2016
(HealthDay)—For patients with type 2 diabetes on background glimepiride therapy, but not metformin, addition of ranolazine is associated with a significant reduction in hemoglobin A1c (HbA1c), according to research published ...

Diacerein reduces mean hemoglobin A1c levels in T2DM

August 25, 2017
(HealthDay)—An immune-modulator anti-inflammatory drug, diacerein, reduces the mean hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes, according to a study published online Aug. 17 in Diabetes Care.

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012
(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Liraglutide tops lixisenatide as add-on to metformin in T2DM

June 28, 2016
(HealthDay)—For patients with type 2 diabetes taking metformin, add-on liraglutide is more effective than lixisenatide for improving glycemic control, according to a study published online June 16 in Diabetes Care.

Glucagon receptor antagonist ups blood pressure in T2DM

February 23, 2017
(HealthDay)—For patients with type 2 diabetes, once-daily treatment with the glucagon receptor antagonist LY2409021 is associated with increases in ambulatory blood pressure (BP), according to a study published online Feb. ...

Recommended for you

Lentils significantly reduce blood glucose levels, study reveals

June 13, 2018
Replacing potatoes or rice with pulses can lower your blood glucose levels by more than 20 per cent, according to a first-ever University of Guelph study.

Is there a link between diabetes and Parkinson's disease?

June 13, 2018
People with type 2 diabetes may have an increased risk of having a diagnosis of Parkinson's disease later in life, according to a large study published in the June 13, 2018, online issue of Neurology, the medical journal ...

Double-checking diabetes medications may reduce re-hospitalizations

June 11, 2018
Clinicians may take upwards of 15 minutes to double-check a patient's medication list in an electronic health record system, but according to a new study, this reconciliation process may be well worth the time for diabetes ...

How a gene linked to obesity could provide new insights into diabetes

June 8, 2018
A gene previously linked with obesity has been found to affect how the body processes insulin, with potential implications for some forms of diabetes.

New hope from the 'seven year switch' in type 1 diabetes

June 8, 2018
New research has shown that the rapid decline in insulin production that causes Type 1 diabetes continues to fall over seven years and then stabilises.

Diabetes results from a breakdown of epigenetic control

June 5, 2018
Diabetes affects more than 400 million individuals worldwide. In what is becoming a paradigm shift, researchers have begun to find that the disease may result in part through pancreatic beta cells losing their functional ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.